JP2015518835A5 - - Google Patents

Download PDF

Info

Publication number
JP2015518835A5
JP2015518835A5 JP2015512776A JP2015512776A JP2015518835A5 JP 2015518835 A5 JP2015518835 A5 JP 2015518835A5 JP 2015512776 A JP2015512776 A JP 2015512776A JP 2015512776 A JP2015512776 A JP 2015512776A JP 2015518835 A5 JP2015518835 A5 JP 2015518835A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
peptide
seq
administered
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2015512776A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015518835A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/041063 external-priority patent/WO2013173411A1/en
Publication of JP2015518835A publication Critical patent/JP2015518835A/ja
Publication of JP2015518835A5 publication Critical patent/JP2015518835A5/ja
Withdrawn legal-status Critical Current

Links

JP2015512776A 2012-05-16 2013-05-15 癌幹細胞を標的とした癌ワクチン Withdrawn JP2015518835A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261647615P 2012-05-16 2012-05-16
US61/647,615 2012-05-16
PCT/US2013/041063 WO2013173411A1 (en) 2012-05-16 2013-05-15 Cancer stem cell targeted cancer vaccines

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018008606A Division JP2018109004A (ja) 2012-05-16 2018-01-23 癌幹細胞を標的とした癌ワクチン

Publications (2)

Publication Number Publication Date
JP2015518835A JP2015518835A (ja) 2015-07-06
JP2015518835A5 true JP2015518835A5 (enExample) 2016-07-07

Family

ID=49584234

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2015512776A Withdrawn JP2015518835A (ja) 2012-05-16 2013-05-15 癌幹細胞を標的とした癌ワクチン
JP2018008606A Pending JP2018109004A (ja) 2012-05-16 2018-01-23 癌幹細胞を標的とした癌ワクチン
JP2020065482A Pending JP2020117519A (ja) 2012-05-16 2020-04-01 癌幹細胞を標的とした癌ワクチン
JP2022104015A Pending JP2022130585A (ja) 2012-05-16 2022-06-28 癌幹細胞を標的とした癌ワクチン
JP2024110688A Pending JP2024156682A (ja) 2012-05-16 2024-07-10 癌幹細胞を標的とした癌ワクチン

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2018008606A Pending JP2018109004A (ja) 2012-05-16 2018-01-23 癌幹細胞を標的とした癌ワクチン
JP2020065482A Pending JP2020117519A (ja) 2012-05-16 2020-04-01 癌幹細胞を標的とした癌ワクチン
JP2022104015A Pending JP2022130585A (ja) 2012-05-16 2022-06-28 癌幹細胞を標的とした癌ワクチン
JP2024110688A Pending JP2024156682A (ja) 2012-05-16 2024-07-10 癌幹細胞を標的とした癌ワクチン

Country Status (16)

Country Link
US (3) US10485858B2 (enExample)
EP (4) EP3912634B1 (enExample)
JP (5) JP2015518835A (enExample)
CA (2) CA3183703A1 (enExample)
CY (1) CY1124512T1 (enExample)
DK (1) DK3536334T3 (enExample)
ES (3) ES2967342T3 (enExample)
HR (1) HRP20211432T1 (enExample)
HU (1) HUE056350T2 (enExample)
LT (1) LT3536334T (enExample)
PL (1) PL3536334T3 (enExample)
PT (1) PT3536334T (enExample)
RS (1) RS62406B1 (enExample)
SI (1) SI3536334T1 (enExample)
SM (1) SMT202100545T1 (enExample)
WO (1) WO2013173411A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013173411A1 (en) 2012-05-16 2013-11-21 Stemline Therapeutics, Inc Cancer stem cell targeted cancer vaccines
US11712465B2 (en) 2016-10-07 2023-08-01 Enterome S.A. Microbiota sequence variants of tumor-related antigenic epitopes
IL296165B2 (en) 2016-10-07 2023-10-01 Enterome S A Immunogenic compounds for cancer treatment
CN117801069A (zh) 2016-10-07 2024-04-02 恩特罗姆公司 用于癌症疗法的免疫原性化合物
ES2935702T3 (es) 2018-04-11 2023-03-09 Enterome S A Péptidos antigénicos para la prevención y el tratamiento del cáncer
US20210106652A1 (en) * 2018-04-11 2021-04-15 Enterome S.A. Immunogenic Compounds For Treatment Of Fibrosis, Autoimmune Diseases And Inflammation
WO2021155501A1 (zh) * 2020-02-05 2021-08-12 瓦克斯恩有限公司 生存素与gm-csf的融合体、编码dna、重组表达载体、抗肿瘤疫苗及其应用

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
DE4121547A1 (de) 1991-06-28 1993-01-14 Daimler Benz Ag Mehrschichtisolierfolie
US6419931B1 (en) 1991-08-26 2002-07-16 Epimmune Inc. Compositions and methods for eliciting CTL immunity
ATE161190T1 (de) 1991-10-07 1998-01-15 Biogen Inc Vorbeugungsmethode oder behandlung von, durch antigen-präsentierende zellen hervorgerufene, hautkrankheiten mittels inhibitoren der cd2/lfa-3 wechselwirkung
US6162432A (en) 1991-10-07 2000-12-19 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
AU712441B2 (en) 1994-12-14 1999-11-04 Scripps Research Institute, The In vivo activation of tumor-specific cytotoxic T cells
US5837231A (en) 1996-06-27 1998-11-17 Regents Of The University Of Minnesota GM-CSF administration for the treatment and prevention of recurrence of brain tumors
WO2001058479A1 (en) 2000-02-08 2001-08-16 The Penn State Research Foundation Immunotherapy using interleukin 13 receptor subunit alpha 2
CA2671940A1 (en) 2000-02-23 2001-08-30 Cv Therapeutics, Inc. Identification of partial agonists of the a2a adenosine receptor
US20030044406A1 (en) 2001-03-02 2003-03-06 Christine Dingivan Methods of preventing or treating inflammatory or autoimmune disorders by administering CD2 antagonists in combination with other prophylactic or therapeutic agents
NZ528076A (en) 2001-03-02 2005-09-30 Medimmune Inc Methods of preventing or treating inflammatory or autoimmune disorders by administering integrin alphav beta3 antagonists with an immunomodulatory agents, anti-inflammatory agents, TNF-alpha antagonists or CD2 binding molecules
FR2838742B1 (fr) 2002-04-23 2004-07-09 Inst Nat Sante Rech Med Epitopes t de l'antigene epha2
WO2004087758A2 (en) 2003-03-26 2004-10-14 Neopharm, Inc. Il 13 receptor alpha 2 antibody and methods of use
KR101224235B1 (ko) 2003-04-11 2013-01-25 메디뮨 엘엘씨 재조합 ｉｌ­９ 항체 및 그의 용도
JP2004353820A (ja) 2003-05-30 2004-12-16 Toyota Motor Corp トリポート型等速ジョイント部品およびトリポート型等速ジョイント
CA2533789C (en) 2003-07-30 2013-09-17 University Of Pittsburgh Of The Commnonwealth System Of Higher Education Epha2 t-cell epitope agonists and uses therefor
KR20060130038A (ko) 2003-10-15 2006-12-18 메디뮨 인코포레이티드 리스테리아에 의거한 ＥｐｈＡ２ 백신
JP4926714B2 (ja) 2003-11-19 2012-05-09 サーバック エーピーエス Ｂｃｌ−２ファミリ−に属するタンパク質およびそのフラグメント、ならびに癌患者におけるそれらの使用
US20050153923A1 (en) 2003-12-04 2005-07-14 Kinch Michael S. Targeted drug delivery using EphA2 or EphA4 binding moieties
WO2006034334A2 (en) 2004-09-21 2006-03-30 University Of Pittsburgh Of The Commonwealth System Of Higher Education Peptide analogs capable of enhancing stimulation of a glioma-specific ctl response
CN101072875B (zh) 2004-12-07 2011-05-18 东丽株式会社 新型癌抗原肽及其用途
DK1853305T3 (en) 2005-02-04 2014-12-01 Survac Aps Survivin-peptide vaccine
US20070104689A1 (en) * 2005-09-27 2007-05-10 Merck Patent Gmbh Compositions and methods for treating tumors presenting survivin antigens
EP1945754B1 (en) 2005-10-31 2014-07-23 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US8343461B2 (en) 2006-03-08 2013-01-01 Wake Forest University Health Sciences Molecular signature of cancer
ATE539079T1 (de) 2006-03-23 2012-01-15 Novartis Ag Imidazochinoxalinverbindungen als immunmodulatoren
CA2646891A1 (en) 2006-03-23 2007-09-27 Novartis Ag Immunopotentiating compounds
EP2783700A1 (en) 2006-09-07 2014-10-01 Stemline Therapeutics, Inc. Cancer stem cell-targeted cancer therapy
US20080118432A1 (en) 2006-09-07 2008-05-22 Ivan Bergstein Monitoring cancer stem cells
WO2008039969A2 (en) 2006-09-28 2008-04-03 Cedars-Sinai Medical Center Cancer vaccines and vaccination methods
WO2008091908A2 (en) 2007-01-22 2008-07-31 Raven Biotechnologies Human cancer stem cells
CA2694011C (en) 2007-07-19 2016-01-12 Health Research, Inc. Survivin peptides as cancer vaccines
ES2536465T3 (es) 2008-10-01 2015-05-25 Immatics Biotechnologies Gmbh Composición de péptidos tumor-asociados y relacionados con la vacuna contra el cáncer para el tratamiento de glioblastoma (GBM) y otros cánceres
US20110223187A1 (en) 2010-02-15 2011-09-15 Vafa Shahabi Live listeria-based vaccines for central nervous system therapy
GB201004551D0 (en) 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
WO2012027379A2 (en) 2010-08-24 2012-03-01 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Interleukin-13 receptor alpha 2 peptide-based brain cancer vaccines
US8801711B2 (en) * 2011-06-16 2014-08-12 Clifford T. Solomon Skull clamp system with pressure limiting and alarm systems
WO2013173411A1 (en) 2012-05-16 2013-11-21 Stemline Therapeutics, Inc Cancer stem cell targeted cancer vaccines

Similar Documents

Publication Publication Date Title
Juratli et al. Current status of local therapy in malignant gliomas—a clinical review of three selected approaches
MX2017014532A (es) Vacunas para el tratamiento y prevencion del cancer.
CR20160018A (es) Nueva inmunoterapia contra diversos tumores como el cáncer de pulmón, incluido el carcinoma de pulmón amicrocítico (nsclc)
MX384315B (es) Agente para el tratamiento y/o prevención de enfermedades asociadas con anormalidades inmunes.
EP4382164A3 (en) Methods for treating or preventing asthma by administering an il-4r antagonist
WO2015193359A3 (en) Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (cll)
MX2013002207A (es) Vacunas contra el cancer cerebral basadas en peptido alfa 2 del receptor de interleucina 13.
WO2016105542A3 (en) Nanoparticle compositions and methods for immunotherapy
EP4253401A3 (en) Personalized immunotherapy against several neuronal and brain tumors
JP2015110588A5 (enExample)
EP4223772A3 (en) Optimized factor viii gene
IN2014CH00391A (enExample)
MX365205B (es) Preparaciones liofilizadas de melfalán flufenamida.
MX2016014414A (es) Vacuna de peptido que comprende un peptido ras mutante y un agente quimioterapeutico.
WO2015140172A3 (en) A medicament for use in a method of inducing or extending a cellular cytotoxic immune response
MX2021002513A (es) Composicion que comprende desintegrina y metaloproteinasa con motivos tipo i de trombospondina 13 (adamts13) para administracion subcutanea.
PH12014501388A1 (en) A recombinant koi herpesvirus (khv) and vaccine for the prevention of a disease caused by khv
RU2016108808A (ru) Терапевтическое применение vegf-c и ccbe1
EP4253419A3 (en) A vaccine in combination with an immune checkpoint inhibitor for use in treating cancer
JP2012102105A5 (enExample)
WO2014160987A3 (en) Vaccines comprising leishmania polypeptides for the treatment and diagnosis of leishmaniasis
EP4321218A3 (en) Cancer stem cell targeted cancer vaccines
WO2013096335A8 (en) ADMINISTRATION OF AN ANTAGONIST OF α5β1 FOR ANTI-ANTIOGENESIS AND CANCER TREATMENT
EP4282485A3 (en) Dosage regimen for pegylated interferon
IN2014CH00390A (enExample)